Lost in translation, FDA slaps Chinese drugmaker with warning letter for mixing up APIs

China flag
China's Guangdong Zhanjiang Jimin Pharmaceutical has been banned from shipping products to the U.S. and slapped with a warning letter after FDA inspectors found big problems at its manufacturing plant.

The FDA has slapped a warning letter on a Chinese drug manufacturer that shipped multiple lots of an OTC product to the U.S. containing the wrong API because the company messed up a translation.

A warning letter was issued Oct. 30 to OTC drugmaker Guangdong Zhanjiang Jimin Pharmaceutical laying out a host of issues, including discovering that it was using the wrong API for an anti-itch product that was labeled as containing hydrocortisone.

“Our investigators reviewed records showing that the active pharmaceutical ingredient (API) actually used in this product was dexamethasone acetate—a different API,” the warning letter said. “When our investigator inquired about the incorrect API, your firm stated that there was a translation mistake, and the two APIs were believed to be the same ingredient. Your quality unit approved multiple lots of this drug product for distribution to the United States containing the incorrect active ingredient.”

The FDA says the company in August did recall the products but never provided any details on its investigation into how the mistake occurred and what it would do to prevent the same issue from occurring in the future. On top of that, the FDA told Jimin Pharmaceutical its Piyanping Anti-Itch Lotion is not an approved product.

The company also was not adequately testing for microbial contamination and wasn’t testing all of its batches for strength and the identity of the APIs in them.

The FDA added the Chinese company to the import alert list in August and has recommended it hire a consultant to help it figure out FDA regulations if it intends to sell products in the U.S. at a later date.

Suggested Articles

Amgen buys out Astellas Japanese joint venture. Sun Piaoyang steps down as Hengrui chairman. Moderna-NIH and Inovio work on coronavirus vaccines.

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.